Literature DB >> 28455162

The EPISOD study: long-term outcomes.

Peter B Cotton1, Qi Pauls2, Jamila Keith3, Andre Thornhill2, Douglas Drossman4, April Williams3, Valerie Durkalski-Mauldin2.   

Abstract

BACKGROUND AND AIMS: The EPISOD (Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction) study randomized patients with post-cholecystectomy pain, and little or no objective evidence for biliary obstruction, to sphincterotomy or sham intervention. Results at 1 year showed no benefit for the active treatment. We now report the outcomes at up to 5 years.
METHODS: One hundred three patients completing 1 year, and still blinded to treatment allocation, were enrolled and followed by phone every 6 months for a median of 58 months (range, 17-71 months). Their success was assessed at the final visit by 2 criteria: (1) a low pain score (Recurrent Abdominal Pain and Disability instrument [RAPID] <6) and (2) much or very much improved on the Patients' Global Impression of Change (PGIC) questionnaire (both with no repeat intervention and not taking narcotics).
RESULTS: By the RAPID criteria, success rates for the patients in the sphincterotomy and sham arms were similar: 26/65 (40%) versus 16/38 (42%), respectively. However, by the PGIC criteria, actively treated patients fared worse: 16/43 (37%) versus 16/22 (73%). A total of 75 patients underwent active treatment during the entire study. Their success rate by the RAPID criteria was 31 (41%) compared with 16 (62%) who had no active treatment at any time.
CONCLUSIONS: These data confirm our initial report that endoscopic sphincterotomy is no better than sham intervention in these patients (and, by some criteria, worse), and that ERCP can no longer be recommended. The patients have genuine and often severe symptoms, and further research is needed to establish effective management. (Clinical trial registration number: 00688662 05/3/2008.).
Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28455162     DOI: 10.1016/j.gie.2017.04.015

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  6 in total

1.  Why did the sham-treated EPISOD study subjects do so well? Important lessons for research and practice.

Authors:  Peter B Cotton
Journal:  Gastrointest Endosc       Date:  2018-11-14       Impact factor: 9.427

Review 2.  Biliary complications after liver transplantation: current perspectives and future strategies.

Authors:  Bianca Magro; Matteo Tacelli; Alessandra Mazzola; Filomena Conti; Ciro Celsa
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 7.293

Review 3.  Etiologies of Long-Term Postcholecystectomy Symptoms: A Systematic Review.

Authors:  Carmen S S Latenstein; Sarah Z Wennmacker; Judith J de Jong; Cornelis J H M van Laarhoven; Joost P H Drenth; Philip R de Reuver
Journal:  Gastroenterol Res Pract       Date:  2019-04-14       Impact factor: 2.260

4.  Clinical course of biliary-type sphincter of Oddi dysfunction: endoscopic sphincterotomy and functional dyspepsia as affecting factors.

Authors:  Hiroyuki Miyatani; Hirosato Mashima; Masanari Sekine; Satohiro Matsumoto
Journal:  Ther Adv Gastrointest Endosc       Date:  2019-08-12

5.  The presence and outcome of biliary sphincter disorders in liver-transplant recipients according to the Rome IV classification.

Authors:  Alejandro Fernandez-Simon; Oriol Sendino; Karina Chavez-Rivera; Henry Córdova; Jordi Colmenero; Gonzalo Crespo; Yilliam Fundora; Franco Samaniego; Pablo Ruiz; Constantino Fondevila; Miquel Navasa; Andrés Cárdenas
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-06-28

6.  Combined extracorporeal shock wave lithotripsy and endoscopic treatment for pain in chronic pancreatitis (SCHOKE trial): study protocol for a randomized, sham-controlled trial.

Authors:  Søren S Olesen; Asbjørn M Drewes; Rajesh Gaud; Manu Tandan; Sundeep Lakhtakia; Mohan Ramchandani; G V Rao; D Nageshwar Reddy; Rupjyoti Talukdar
Journal:  Trials       Date:  2020-04-16       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.